Saturday, March 06, 2021 10:48:04 PM
Bear with me:
(1)The time from onset of symptoms to hospitalization is between 3 and 10 days.
(2)The median time from onset of Covid symptoms to dyspnea is 5-8 days.
(3)The median time to ICU admission from onset of symptoms is 10 days as reported by the CDC.
(4)The virus can no longer be cultured from patient specimens 10 days after onset of symptoms (according to the CDC).
So most of the patients in the clinical trial have likely been symptomatic for at least five days and some even 10 days before they are considered moderate or severe.
The viral load is already decreasing by the time patients are really sick in the ICU and the problem isn't viral replication but the uncontrolled cytokine cascade which is the inflammatory response gone haywire. I am definitely not objecting or minimizing the potential benefit of anti-virals on the back end of the infectious process but I think anti-inflammatories will prove to play a much bigger role in patient improvement for mod/severe Covid.
IMO, Brilacidin's anti-inflammatory properties may be more important for patient recovery than its anti-viral properties. Dexamethasone is more effective than Remdesivir in the moderate/severe Covid population. Earlier in the disease, Remdesivir may prove more effective as limiting the viral load may limit the cytokine cascade.
I know that the argument for Brilacidin has been built on its anti-viral properties but the course of disease changes therapeutic intervention strategy from anti-viral to anti-inflammatory. Brilacidin is incredibly intriguing because it has both potent anti-viral and anti-inflammatory properties.
As a potential Covid therapy for moderate/severe patients, I am more focused on Brilacin's anti-inflammatory potential. For patients earlier in the disease process (pre-hospitalization or minimally symptomatic) I'd probably focus more on the anti-viral properties.
It may be a little out there but I hope it's food for thought.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM